Tumor suppressor genes act in signaling networks that protect against tumor initiation and progression, and can be inactivated by deletions, point mutations, or promoter hypermethylation. Although tumor suppressors are rarely considered direct drug targets, they can negatively regulate pro-oncogenic signaling proteins that are amenable to small molecule inhibition. For instance, NF1 inhibits the Ras signaling pathway, which is deregulated in many cancers and has been pursued for its therapeutic potential (Downward 2003) . Similarly, PTEN inhibits the PI3-kinase pathway, and inhibitors of PI3K pathway components such as PI3K, AKT, and mTORs have entered clinic trials (Luo et al. 2003) .
Recurrent chromosomal deletions found in sporadic cancers often contain tumor suppressor genes. For example, PTEN loss on chromosome 10q23 frequently occurs in various cancers and promotes tumorigenesis by deregulating the PI3 kinase pathway (Maser et al. 2007) . Similarly, heterozygous deletions on chromosome 8p22 in many hepatocellular carcinomas (HCC) (Jou et al. 2004 ) and other cancer types, including carcinomas of the breast, prostate, colon, and lung (Matsuyama et al. 2001; Durkin et al. 2007) . Several genes, including DLC1, MTUS1, FGL1 and TUSC3, have been identified as candidate tumor suppressors in this region (Yan et al. 2004) . Deleted in Liver Cancer 1 (DLC1) is a particularly attractive candidate owing to its genomic deletion, promoter methylation, and underexpressed mRNA in cancer (Yuan et al. 1998 (Yuan et al. , 2003a Ng et al. 2000; Wong et al. 2003; Guan et al. 2006; Seng et al. 2007; Ying et al. 2007; Zhang et al. 2007; Pike et al. 2008 ; for review, see Durkin et al. 2007) .
Despite its potential importance, functional data implicating DLC1 loss in tumorigenesis are lacking. DLC1 encodes a RhoGAP protein that catalyzes the conversion of active GTP-bound RhoGTPase (Rho) to the inactive GDP-bound form and thus suppresses Rho activity (Yuan et al. 1998 ). DLC1 has potent GAP activity for RhoA and limited activity for CDC42 (Wong et al. 2003; Healy et al. 2008) . When overexpressed, DLC1 inhibits the growth of tumor cells and xenografts (Yuan et al. 2003b (Yuan et al. , 2004 Zhou et al. 2004; Wong et al. 2005; Kim et al. 2007 ), but whether this requires its Rho-GAP activity or other functions remains unresolved (Qian et al. 2007; Liao et al. 2007 ). Most functional studies to date have relied on DLC1 overexpression and, as yet, none have documented that loss of DLC1 promotes transformation in vitro or tumorigenesis in vivo. Indeed, homozygous dlc1 knockout mice die around embryonic day 10.5 (E10.5), and there is no overt phenotype in dlc1 heterozygous mice (Durkin et al. 2005) .
Our laboratory recently developed a "mosaic" mouse model whereby liver carcinomas can be rapidly produced with different genetic alterations by manipulation of cultured embryonic liver progenitor cells (hepatoblasts) followed by transplantation into the livers of recipient mice (Zender et al. 2005 (Zender et al. , 2006 . We previously used this model to identify new oncogenes in HCC, which could be characterized in an appropriate biological and genetic context (Zender et al. 2006 ). Furthermore, using this system, we showed that shRNAs capable of suppressing gene function by RNAi could recapitulate the consequences of tumor suppressor gene loss on liver carcinogenesis (Zender et al. 2005; Xue et al. 2007 ). Here we combine this mosaic model and RNAi to validate DLC1 as a potent tumor suppressor gene and study its action in vivo.
Results and Discussion
Studies using low-resolution genome scanning methods have identified chromosome 8p deletions as common lesions in liver carcinoma and other tumor types. To confirm and extend these observations, we examined a se- [Keywords: DLC1; HCC; RNAi; RhoA; mouse model] ries of data sets of copy number alterations in HCC obtained using representational oligonucleotide microarray analysis (ROMA), a variation of array-based CGH that enables genome scanning at high resolution (Lucito et al. 2003) . In a panel of 86 liver cancers, heterozygous deletions encompassing the DLC1 were observed in 59 tumors ( Fig. 1A,B ; data not shown). Consistent with previous reports, these deletions were large (>5 Mb), encompassing >20 annotated genes but invariably included the DLC1 locus. Indeed, heterozygous deletions of DLC1 occurred more frequently than those observed for the wellestablished tumor suppressors such as INK4a/ARF, PTEN, and TP53 (Fig. 1C ). Furthermore, DLC1 deletions were nearly as common as those for TP53 in other major tumor types such as lung, colon, and breast (Fig. 1C ). Again, most 8p deletions were large, although in breast cancer DLC1 resided at a local deletion epicenter reminiscent of that surrounding the INK4a/ARF locus on chromosome 9p21 (Fig. 1D,E) . Although we did not examine the status of the remaining allele in this tumor cohort, studies suggest that it can be silenced by promoter methylation (Yuan et al. 2003a ; for review, see Durkin et al. 2007 ). Together, these data suggest that DLC1 loss plays an important role in human cancer but, in the absence of functional validation, are not conclusive.
Human liver tumor cells with 8p deletions invariably expressed low DLC1 mRNA (Supplemental Fig. S1 ). We also examined a series of murine liver carcinomas produced from embryonic hepatoblasts (Zender et al. 2006 ). None of the tumors we analyzed contained deletions on mouse chromosome 8qA4, the region containing the murine dlc1 gene (data not shown), although many displayed reduced dlc1 mRNA levels compared with parental hepatoblasts or immortalized liver progenitor cells ( Fig. 1F ). Thus, down-regulation of DLC1 expression can occur during murine hepatocellular carcinogenesis.
If DLC1 is a bona fide tumor suppressor in humans, we hypothesized that reductions in DLC1 levels should promote HCC in mice. To test this hypothesis and to avoid complications associated with the embryonic lethality of dlc1 knockout animals, we decided to knockdown DLC1 expression in hepatoblasts using RNAi and test the ability of these cells to form tumors following engraftment into the livers of recipient mice. We therefore generated microRNA-based shRNA capable of efficiently suppressing DLC1 expression at mRNA and protein levels ( Fig. 2A,B ).
Our genomic analyses, together with previous reports, identify amplifications of the Myc oncogene and inactivation of the p53 tumor suppressor as common events in HCC (Staib et al. 2003 ; data not shown). We therefore decided to test the impact of DLC1 loss in cells coexpressing Myc and lacking p53, which together are only weakly oncogenic in this model (Zender et al. 2006 ). p53deficient liver progenitor cells were cotransduced with one retrovirus expressing Myc and another coexpressing a DLC1 shRNA with a GFP reporter, thus enabling imaging of cells with reduced DLC1 expression (Supplemental Fig. S2A,B ). Interestingly, DLC1 knockdown had little impact on the colony forming ability of liver progenitor cells in vitro ( Fig. 2C; Supplemental Fig. S3A ).
Genetically modified liver progenitors were seeded into the livers of syngeneic recipients to assess their ability to form tumors in situ. In contrast to the modest impact of DLC1 loss in vitro, DLC1 shRNAs significantly accelerated tumor onset in vivo (P value < 0.0001 for shDLC1-1 and P < 0.0005 for shDLC1-2) ( Fig. 2D,E) . In fact, at 57 d post-transplantation, GFP-positive tumor nodules were observed in the livers of most animals receiving cells harboring DLC1 shRNAs, whereas the control animals showed no macroscopically detectable tumor burden ( Fig. 2E ). Furthermore, the pathology of tumors derived from DLC1 knockdown resembled aggressive human HCC and displayed a high proliferative index as assessed by Ki67 immunohistochemistry (Fig. 2F ). Tumors also expressed the HCC markers ␣fetoprotein (AFP) and albumin (Supplemental Fig. S3B ). These data demonstrate that loss of DLC1 can efficiently promote the development of HCC. We also ectopically expressed the murine dlc1 gene in mouse hepatoma cells and tested their ability to form tumors orthotopically. To this end, we cloned a Myctagged murine dlc1 cDNA and confirmed its ability to produce a protein of the correct molecular weight (Fig.  3A) . A mouse hepatoma cell line harboring a luciferase reporter and expressing oncogenic Ras and undetectable DLC1 (see Fig. 1F, lane 8) was infected with the DLC1expressing retrovirus or an empty vector. Consistent with the literature (Ng et al. 2000) , reintroduction of DLC1 produced a modest effect on proliferation in colony formation assays (Supplemental Fig. S4A,B) .
At 2 wk post-liver transplantation, animals receiving control cells developed aggressive liver tumors revealed by whole-body bioluminescence imaging (Fig. 3B, left) . Mice transplanted with cells expressing DLC1 had a greatly reduced tumor burden ( Fig. 3B [right] , C). Accordingly, explanted livers from control animals harbored disseminated tumor nodules that coexpressed both luciferase and GFP (Fig. 3D, top panel) , whereas livers from mice receiving cells overexpressing DLC1 showed little evidence of tumor formation even using these sensitive imaging reporters (Fig. 3D, bottom) .
Since DLC1 has GAP activity for RhoA (Wong et al. 2003) , we tested whether DLC1 knockdown increased RhoA-GTP levels and mimicked activated RhoA in promoting stress fiber formation, a hallmark of RhoA activity (Wong et al. 2005) . p53-deficient liver progenitor cells harboring Myc and DLC1 shRNAs displayed increased levels of GTP-bound RhoA as assessed by a pull-down assay using a Rhotekin-RBD domain (Kim et al. 2007 ), which selectively binds RhoA-GTP (Fig. 4A,B) . Concordantly, hepatoblasts with reduced DLC1 levels showed a prominent actin stress fiber network as assessed by fluorescent phalloidin labeling actin filaments (Fig. 4C) . Thus, loss of DLC1 recapitulates the effects of activated RhoA on liver epithelial cells in vitro.
To test whether activated RhoA, like loss of DLC1, can promote liver carcinoma formation, we infected p53 −/− liver progenitor cells with retrovirus expressing Myc and a constitutively active RhoA (RhoA V14 ) ( Fig.  4D ) and transplanted the cells into the livers of syngeneic mice. Indeed, enforced expression of RhoA V14 dramatically accelerated tumor formation ( Fig. 4E [P < 0.0001], F; see also Supplemental Fig. S5 ), producing tumors with the pathological features of HCC (data not shown). Thus, DLC1 loss and RhoA activation have similar effects on hepatocellular carcinogenesis.
Although RhoA has been identified as a DLC1 effector, overexpression studies suggest that other DLC1 functions can contribute to its anti-proliferative activities Qian et al. 2007 ). To determine whether RhoA is required for maintaining tumorigenesis stimulated by DLC1 loss, we tested whether suppression of RhoA in DLC1-suppressed hepatoma lines would impact their expansion as subcutaneous tumors in immunocompromised mice. shRNAs capable of down-regulating RhoA to varying degrees (Fig. 5A ) decreased the in vivo growth of two independent murine hepatoma lines with undetectable DLC1 (Fig. 5B, cell lines 1,2 ; Supplemental  Fig. S6A,B) . Of note, none of the shRNAs completely suppressed RhoA expression, and their ability to limit tumor expansion was proportional to their knockdown efficiency ( Supplemental Fig. S6A ). The impact of these shRNAs was less pronounced in hepatoma cell lines with higher DLC1 levels (Fig. 5B, cell lines 3,4 ; Supplemental Fig. S6C,D) . Although complete inhibition of RhoA activity might be generally cytostatic (see Piekny et al. 2005) , these data suggest that RhoA is required for maintaining the growth of tumors with attenuated DLC1 activity.
RhoA signals through ROCK kinase and other mediators to activate a downstream kinase cascade regulating cell mobility and cytoskeleton remodeling (Boettner and Van Aelst 2002; Sahai and Marshall 2002; Benitah et al. 2004; Jaffe and Hall 2005) . As DLC1 loss leads to in-creased RhoA activation and RhoA is important for DLC1-mediated tumorigenesis, we hypothesized that DLC1 loss might sensitize tumor cells to inhibitors of RhoA effectors. As an initial test of this idea, we compared colony formation of p53 −/− ;Myc liver progenitor cells infected with control or DLC1 shRNAs in the presence of Y27632 or Fasudil, two distinct small molecule compounds capable of blocking ROCK kinase activity. These agents selectively suppress colony formation in cells harboring a DLC1 shRNA (Fig. 5C,D) , although another putative ROCK inhibitor (H1152) was generally toxic (data not shown). Still, these pharmacologic results are consistent with the genetic studies indicating a dependency on Rho signaling in DLC1-deficient cells.
In this study, we combined in vivo RNAi and a mosaic mouse model of HCC to study the impact of DLC1 loss on liver carcinogenesis in mice, which to date has not been possible owing to the embryonic lethality of DLC1 knockout animals. We show that DLC1 loss, when combined with other oncogenic lesions, promotes HCC in vivo and that RhoA activation is both necessary and sufficient for its effects. In our survey of copy number alterations in human tumors, 8p22 deletions encompassing DLC1 occurred in >60% of heptocellular carcinomas as well as a large portion of human lung, breast, and colon carcinomas (see also Durkin et al. 2007) . Similarly, RhoA is up-regulated in HCC and many other tumor types (Sahai and Marshall 2002; Fukui et al. 2006 ). Although other tumor suppressor genes may also reside in the 8p region, our results demonstrate that DLC1 is functionally important and highlight the potential importance of the RhoA signaling network in epithelial cancers. Molecularly targeted therapies have been devised for inhibiting several oncogenic pathways, including those affected by BCR-ABL, activated Ras and PI3kinase (Downward 2003; Luo et al. 2003) . Although tumor suppressors are generally not amenable to direct therapeutic targeting, their mutation may confer a cellular dependency on downstream oncogenic proteins that can be inhibited with small molecule drugs. In this regard, the impact of DLC1 loss may parallel that produced by loss of PTEN, which deregulates the PI3K pathway and can sensitize cells to pharmacological inhibitors of downstream effectors such as mTOR (Maser et al. 2007) . Our data indicate that RhoA is required for maintaining at least some tumors driven by DLC1 loss, and that cells with disabled DLC1 are particularly sensitive to inhibitors that target at least one RhoA effector. Clearly, more studies will be required to confirm and extend these observations; nevertheless, the high frequency of DLC1 loss in human cancer implies that pharmacologic intervention of the signaling pathways modulated by DLC1 may have broad therapeutic utility.
Material and methods

Plasmid construction
Two miR30 design shRNAs (codex accession HP_260153 and HP_255554) targeting mouse DLC1 were subcloned from the pSM2 RNAi codex library vector into the MSCV-SV40-GFP vector. The fulllength mouse DLC1 was amplified from a RIKEN cDNA (M5C1068G17) and cloned into the MSCV-PGK-PIG vector harboring 6xMyc tag at the N terminus. Constitutive active RhoA (RhoA V14 ) was cloned into the MSCV-IRES-GFP. Myc was cloned into pWZL-Neo.
Generation and characterization of liver carcinomas
Embyronic heptoblasts were isolated from E13.5 embryos, enriched by an E-cadherin immunoselection, and cultured as described (Zender et al. 2005) . Cells with transduced with retroviral vectors (Xue et al. 2007) , expanded briefly in culture, and transplanted into the spleen of retrorsine pretreated mice where the progenitor cells engraft the liver (Zender et al. 2005) . Animals were treated with CCl 4 to stimulate tumor growth (Zender et al. 2006) . For subcutaneous tumor growth, 2 × 10 6 cells were injected into the flanks of nude mice and monitored as described (Zender et al. 2006) . Fluorescence and bioluminescence imaging of tumor-bearing mice was as described (Xue et al. 2007 ). For colony formation assays, 5000 cells were plated; after 6-8 d, colony formation was quantified by the Multigauge software (FujiFilm). Histopathological evaluation of murine liver carcinomas was performed by an experienced pathologist (S.S.). Ki67 staining was performed using standard protocols on paraffin-embedded tumor sections.
Gene activity and expression
RhoA-GTP pull-down assay was performed using EZ-detect GTPase activation kit (Pierce). For immunoblotting, fresh tumor tissue or cell pellets were lysed in Laemmli buffer using a tissue homogenizer. Equal amounts of protein (16 µg) were separated on 10% SDS-polyacrylamide gels and transferred to PVDF membranes. Blots were probed with antibodies against RhoA (1:1000; Santa Cruz Biotechnologies, 26C4), Myc-Tag (1:1000; Abcam, 9E10), or Tubulin (1:5000; B-5-1-2, Sigma). For immunofluorescence, cells were serum-starved for 24 h, fixed, blocked with 5% goat serum, and incubated with 1:1000 Alexa 594-conjugated phalloidin (Invitrogen). Images were captured under a 40× lens of a confocal microscope (Zeiss). To assess mRNA expression, hepatoma cells or tumors were freshly homogenized in Trizol (Gibco) and RNA was purified with Qiagen RNeasy columns and converted to cDNA using TaqMan reverse transcription reagents (Applied Biosystems). qPCR reactions were done in triplicate with SYBR Green PCR Master Mix (Applied Biosystems). The expression level of each gene was normalized to ␤actin. Primer sequences can be found in the Supplemental Material.
Gene copy number analysis of human tumors
The ROMA data sets used in this study were obtained by analyzing panels of primary tumors (Hicks et al. 2006 ; S. Powers, S.W. Lowe, R. Lucito, and M. Wigler, in prep.) . Copy-number profiles underwent normalization, segmentation, and masking of frequent copy number polymorphisms (Hicks et al. 2006) . Deletion frequencies for DLC1 and other relevant genes were compared with all other genes found in the NCBI Entrez Gene database as described in the Supplemental Material and as well were described in Krasnitz et al. (A. Krasnitz and M. Wigler, in prep.) .
